Clinical Science Institute

Summary

Clinical Science Institute is a medical facility located in Santa Monica, California. This center is recognized for care of Atopic Dermatitis, Psoriasis, Plaque Psoriasis, Medical Device Dermatitis, Eczema and other specialties. Clinical Science Institute is involved with conducting 88 clinical trials across 39 conditions. There are 2 research doctors associated with this hospital, such as Paul Yamauchi and Paul Steven Yamauchi.

Top PIs

Clinical Trials running at Clinical Science Institute

Atopic Dermatitis

Chronic Urticaria

Medical Device Dermatitis

Systemic Lupus Erythematosus

Cutaneous Lupus Erythematosus

Plaque Psoriasis

Discoid Lupus

Barzolvolimab

for Eczema

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Recruiting

0 awards

Phase 2

3 criteria

PF-08049820

for Eczema

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 years of age or more; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. Eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12, and have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. Participants will have blood and urine tests and must answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to participants receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Recruiting

0 awards

Phase 2

6 criteria